The latest news from the third batch of national picks is expected to open on August 18.

Recently, according to industry sources, a few days ago, the provincial health insurance bureau price collection office head of the meeting in Shanghai, the content of the meeting is mainly to discuss the third batch of tape procurement rules, the current content of the cable next August 18, the end of the release of implementation plans and rules.
in the discussion section on the winning bid rules, the 1.8-fold fuse mechanism and the 50 per cent reduction in prices were unchanged from the second batch of volume procurement rules.
at present, the third batch of national varieties with the volume of procurement and the highest effective declaration price has come out.
on the above-mentioned news, Seiber Blue special author Code Wanxuan analysis of Seiber Blue pointed out that "1.8 times fuse mechanism and price reduction 50%" respectively to limit the price range, price reduction range, and the second batch of consistency is also reasonable in principle - first, the third Batch is the expansion of varieties, the number is still limited (86 standards), and the criteria for the finalists are consistent, from the time point of view, the third batch is close to the second batch in doing, the supply of varieties and competitive pattern slot differenceis, the principle of close to the selection is also reasonable.
further said that it would not be surprising if the next fourth and fifth batch were still at that pace.
the above-mentioned professionals further said, first, from the stability of the rules, to a certain extent means that the mature stereotypes of reform, at least in the third batch of decision-making on the second batch of winning and losing the pattern, the effect is more recognized; In fact, pharmaceutical companies should have given up the illusion long ago, because the overall promotion of centralized procurement is a set-up;
review, we can see that the third batch of national procurement progress as follows - 5 days ago, July 21, Shanghai Sunshine Pharmaceutical Procurement Network officially issued "on the development of some drug-related basic information collection work notice", began part of the basic drug information collection work;
that is to say, in a few days at the earliest, the third round of documents will be officially released.
according to the Cyber Blue query on December 29 last year, the National Joint Purchasing Office issued the "National Drug Centralized Procurement Document", the second batch of national selection of enterprises to determine the following guidelines, the finalists in the price of one of the following conditions, to obtain the proposed selection qualification: generic drug companies, the original research drug enterprises, how to deal with the progress of the national organization of drug centralized procurement to the third batch, normalization mechanism has emerged.
in addition, the pilot provinces of comprehensive medical reform will not have the consistency evaluation of drugs and high-value medical supplies into the scope of collection has formed an irreversible situation in the country. On July 23,
, the General Office of the State Council issued the Notice on the Issue and Deepening of key tasks in the second half of 2020 for the reform of the medical and health system, which clearly stated that the scope of centralized procurement and use of pharmaceutical varieties by state organizations should be expanded in an orderly manner, a pilot project for centralized procurement of high-value medical supplies, and a policy document for reforming and improving the drug procurement mechanism.
pharmaceutical consulting company Beijing Faber Technology Development Co., Ltd. in conjunction with the China Pharmaceutical Market Research Association issued by the "VBP impact on China's pharmaceutical market pattern" article analysis pointed out that the main purpose of tape procurement is to achieve the replacement of generic drugs for the original research drugs, and reduce the virtual high price of generic drugs.
can be said that in the national collection of the game, the main player is the original research and drug companies and domestic head of generic drug companies.
minet data show that 86 product regulations in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales of more than 56 billion yuan, involving a total of 300 pharmaceutical companies.
domestic head pharmaceutical companies are still the core participants - The mininet consistency evaluation database shows that in the third round of collection varieties, China Biopharmaceuticals led by 9 over-rated varieties;
the original research and pharmaceutical enterprises need to actively respond to - the third round of national picketing, Pfizer and Mercadon have 5 varieties included, AstraZeneca, Novartis have 4 varieties included, Squip has 3 varieties included.
national collection has been carried out to the third round, some industry insiders to the Cypress Blue analysis pointed out that, with the state organization of drug centralized procurement into the normal stage, the willingness of foreign pharmaceutical companies to participate will be further strengthened.
expects that there are several kinds of conditions, foreign pharmaceutical companies will be more willing to bid - the company has not invested in the source of the product (expected cost control is better), the subsequent introduction of new products with the product line (the need to maintain the market share of the original varieties for new products to enter the market to lay a good foundation), products in the company in an important position (occupy a large market share, to provide the company with a large number of turnover, enterprises can not afford to lose a large number of risks of losing the market), competitive conditions are not enough to meet the positive form of the pharmaceutical industry
in general, for domestic pharmaceutical companies, because the national collection of varieties is generally the original research and pharmaceutical enterprises occupy the main market advantage, in order to occupy or even seize the market considerations, the domestic pharmaceutical companies between the price killing is more intense.
specific point of view, the attitude of domestic pharmaceutical enterprises to participate in the national organization of drug collection is also divided into several situations - Huahai Pharmaceuticals, Collon Pharmaceuticals, Lepu Pharmaceuticals, belongs to the pharmaceutical enterprises that have been actively involved, such as Huahai Pharmaceuticals in the first round of collection of 7 varieties; Correct judgment, such as stone pharmaceutical group's clopidogrel price reduction of 19% winning bid, before there is no market share, sales for the pure increment of products;
the normalization of collection, pharmaceutical enterprise transformation in the uptoly, the national organization of drug collection of the series effect has been continuously shown.
on the effect of the volume of procurement, the China Pharmaceutical Materials Association Research Institute Policy Research Institute issued one of the pharmaceutical industry development blue book series report "2019 pharmaceutical policy development status report" analysis pointed out that - with the consistency of the evaluation of the number of products more and more, drug centralized procurement will enter the normal operation, provincial and municipal pharmaceutical supplies will be in accordance with policy requirements, price reduction will become a trend, accelerate the rapid shuffle of enterprise shuffle.
is the change of product structure, the change of market pattern, the third is the change of competition mechanism, and the fourth is the change of marketing rules.
the concentration of generic drug production enterprises gradually increased, the replacement of imported products will also accelerate, circulation, pharmaceutical retailing and other industries will also be because of the transmission of policies and face new challenges.
from an enterprise perspective, foreign pharmaceutical companies have made strategic and organizational adjustments, some disbanded medical and sales teams, some shunted pharmaceutical representatives to other teams to make internal staff adjustments, some began to spin off product lines or sell products, and focus on innovative drug areas - such as GlaxoSmithKline's hepatitis B star drug "Hepuddin" (Lamifdin) sold to Fosun Pharmaceuticals.
for domestic enterprises, the normality of volume procurement and the continued expansion of the surface also forced pharmaceutical companies to choose their own positioning - is positioned in the generic drug industry, improve the ability to select varieties and cost control capacity, and accept lower profits;
Guoxin Securities in a research report pointed out that from a long-term logical point of view, the future generic drug enterprises must rely on their own API protection capacity, with cost-end comprehensive advantages in order to survive in the long-term competition;
in general, in the face of drug-belt procurement policy brought about by the pressure on drug prices, the pharmaceutical industry has ushered in a comprehensive transition period.
attached: the third batch of national drug catalog original title: the third batch of national harvest, the latest news came out.